A major milestone for data-driven urology: Three new PIONEER+ papers published using real-world data
Three new papers have recently been published, each using real-world data gathered through the PIONEER+ project, part of the EAU UroEvidenceHub (UEH). These papers dive into metastatic prostate cancer and are based on real-world data from hundreds of thousands of patients across Europe.
These publications mark a major milestone for the PIONEER+ collaboration, demonstrating how large-scale data harmonisation and analysis can deliver meaningful real-world evidence (RWE) in prostate cancer. Efforts are paying off, as they uncover results that would not have been possible in clinical trials. The teams at PIONEER+, a project which started with EU funding and continues to live in the EAU UroEvidenceHub, are asking robust research questions, harmonising data across multiple sources using the OMOP Common Data Model, and ensuring high-quality, reproducible analyses.
The studies represent some of the first examples of big urological data being applied at scale to answer clinically relevant questions in advanced prostate cancer. They show how real-world insights can complement clinical trial evidence and support improved decision-making for clinicians and patients alike.
These papers explore:
- Treatment Trajectories in Metastatic Hormone-sensitive Prostate Cancer: A PIONEER+ Big Data Analysis
- Observational Health Data Analysis of the Cardiovascular Adverse Events of Systemic Treatment in Patients with Metastatic Hormone-sensitive Prostate Cancer: Big Data Analytics Using the PIONEER Platform
- Real-world Evidence on Baseline Characteristics and Treatment in Metastatic Hormone-sensitive Prostate Cancer: Findings from the PIONEER 2.0 Big Data Investigation Group
Real-world data can reveal critical insights into prostate cancer care. These studies identify major variations in how mCRPC is treated, demonstrate real-world differences in outcomes between first-line therapies, and highlight key factors influencing progression from mHSPC to mCRPC. These findings provide actionable evidence to help standardise treatment pathways, inform clinical guidelines, and support more personalised care for men with advanced prostate cancer, that will work better for patients.
PIONEER+ is part of the EAU UroEvidenceHub, an initiative building a trusted ecosystem for data-driven, evidence-based urology. Its goal is to generate reliable, high-quality evidence that advances personalised, patient-centred care. These latest papers mark an important step forward for the EAU UEH's mission to enable real-world evidence generation in urology.